Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Capsaicin

Criteria

Inclusion Criteria:

• Clinical normal physical findings, including BP, pulse rate >45 bpm, ECG and laboratory assessments

• Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg.

• Non-fertile females

Exclusion Criteria:

• History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator.

• History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the Investigator.